Synartro is a Swedish life science company developing local injection treatments that provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our novel delivery technology with existing proven drugs.
The initial focus area is knee OA, a disease with significant demand for treatments with improved efficacy and safety profiles for the growing patient population.
The company is currently finalizing its preparations to move into clinical phase.
The company is seeking investments to enable continued development of its promising lead program SYN321.
For further information, please get in touch with Mia Brundin, CEO.